Hepatocyte Growth Factor (HGF) Binding Proteins
AssigneeAVEO Pharmaceuticals, Inc.
InventorsMay Han, S. Kirk Wright, William M. Winston, JR., Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris
Life of this patent
Estimating the term…
Abstract
The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
Claims12
1-93. (canceled)
A method of inhibiting or reducing proliferation of a tumor cell comprising exposing the cell to an effective amount of an isolated antibody that binds human hepatocyte growth factor (HGF) comprising
- (i) an immunoglobulin light chain variable region comprising a CDRL1 comprising the amino acid sequence of SEQ ID NO. 18, a CDRL2 comprising the amino acid sequence of SEQ ID NO. 19, and a CDRL3 comprising the amino acid sequence of SEQ ID NO. 20;
- and
- (ii) an immunoglobulin heavy chain variable region comprising a CDRH1 comprising the amino acid sequence of SEQ ID NO. 15, a CDRH2 comprising the amino acid sequence of SEQ ID NO. 203, and a CDRH3 comprising the amino acid sequence of SEQ ID NO. 17;
- or an antigen binding fragment of the antibody,
- to inhibit or reduce proliferation of the tumor cell.
95-97. (canceled)
A method of inhibiting or reducing tumor growth in a mammal, the method comprising exposing the mammal to an effective amount of an isolated antibody that binds human hepatocyte growth factor (HGF) comprising
- (i) an immunoglobulin light chain variable region comprising a CDRL1 comprising the amino acid sequence of SEQ ID NO. 18, a CDRL2 comprising the amino acid sequence of SEQ ID NO. 19, and a CDRL3 comprising the amino acid sequence of SEQ ID NO. 20;
- and
- (ii) an immunoglobulin heavy chain variable region comprising a CDRH1 comprising the amino acid sequence of SEQ ID NO. 15, a CDRH2 comprising the amino acid sequence of SEQ ID NO. 203, and a CDRH3 comprising the amino acid sequence of SEQ ID NO. 17;
- or an antigen binding fragment of the antibody,
- to inhibit or reduce proliferation of the tumor.
A method of treating a tumor in a mammal, the method comprising administering to the mammal an effective amount of an isolated antibody that binds human hepatocyte growth factor (HGF) comprising
- (i) an immunoglobulin light chain variable region comprising a CDRL1 comprising the amino acid sequence of SEQ ID NO. 18, a CDRL2 comprising the amino acid sequence of SEQ ID NO. 19, and a CDRL3 comprising the amino acid sequence of SEQ ID NO. 20;
- and
- (ii) an immunoglobulin heavy chain variable region comprising a CDRH1 comprising the amino acid sequence of SEQ ID NO. 15 a CDRH2 comprising the amino acid sequence of SEQ ID NO. 203, and a CDRH3 comprising the amino acid sequence of SEQ ID NO. 17;
- or an antigen binding fragment of the antibody.
(canceled)
Dependencies are inferred from the claim text.